14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
DXCM vs IDXX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, DexCom, Inc. (DXCM) is the stronger overall head-to-head candidate over Idexx Laboratories Inc (IDXX) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). DXCM carries a Unified Composite Score of 50.8/100 (HOLD) at $79.32 (25.3x Forward P/E, 24.0% operating margin), whereas IDXX carries 44.3/100 (HOLD) at $676.21 (40.0x Forward P/E, 32.5% operating margin).
Technical & Structure Timing Caution: DXCM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.0); meanwhile IDXX trades in a Markup technical trend (SURGE options phase, RSI 59.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Medical Devices value chain with $29.9B market capitalization and 24.0% operating margin.
OpEx & R&D Reinvestment39.4% of Rev ($2.01B)
90D Engineering Disclosures0 Published
IDXX Moat ProfileHigh-Margin Pricing Power Moat
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $54.3B market capitalization and 32.5% operating margin.
OpEx & R&D Reinvestment30.2% of Rev ($1.41B)
90D Engineering Disclosures0 Published
Investor FAQ DXCM vs IDXX Key Questions & Quantitative Answers
As of Nov 20, 2026, DexCom, Inc. (DXCM) is the stronger overall head-to-head candidate over Idexx Laboratories Inc (IDXX) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). DXCM carries a Unified Composite Score of 50.8/100 (HOLD) at $79.32 (25.3x Forward P/E, 24.0% operating margin), whereas IDXX carries 44.3/100 (HOLD) at $676.21 (40.0x Forward P/E, 32.5% operating margin). Technical & Structure Timing Caution: DXCM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.0); meanwhile IDXX trades in a Markup technical trend (SURGE options phase, RSI 59.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
DXCM leads the Growth & Scale pillar: DXCM posts +11.2% YoY revenue growth and +2.6% YoY earnings growth on $5.10B TTM revenue (63.4% gross margin, 24.0% operating margin), compared with IDXX at +9.9% YoY revenue growth and +17.9% YoY earnings growth on $4.66B TTM revenue (62.7% gross margin, 32.5% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), DXCM cumulative revenue shifted +352.4% while IDXX shifted +94.6%. In operating R&D and SG&A reinvestment, DXCM deploys 39.4% of Rev ($2.01B) (0 90-day corporate R&D disclosures) versus 30.2% of Rev ($1.41B) (0 disclosures) for IDXX.
DXCM screens cheaper on headline valuation multiples. DXCM trades at 25.3x Forward P/E, 31.6x Trailing P/E, 1.30x PEG, and 5.9x EV/Revenue (33.9% FCF margin), whereas IDXX trades at 40.0x Forward P/E, 46.5x Trailing P/E, 3.24x PEG, and 11.8x EV/Revenue (27.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DXCM (37.7% ROE) versus IDXX (68.9% ROE) capital efficiency.
In options market volatility and institutional positioning, DXCM carries 63.0% implied volatility (15th %ile, Compressed (<25th %ile)), a 0.48x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.59β · 43% Vol realized risk). By comparison, IDXX carries 81.5% implied volatility (34th %ile, Balanced (25th–60th %ile)), a 0.15x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.61β · 81% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.